Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma
A phase 2 trial of Sacituzumab tirumotecan in thymoma and thymic carcinoma, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.
Overview
Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma is a phase 2 interventional study registered as NCT07324629 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 30 participants planned, started 2026-03-13 and due to reach its primary completion in 2028-04. Interventions recorded: Sacituzumab tirumotecan.
Similar pages
not linked directly; found by shared links- TrialSKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer
Shares Sichuan Kelun-Biotech and the tag pipeline.
- TrialA Study of KL590586 in Patients With Advanced Solid Tumors
Shares Sichuan Kelun-Biotech and the tag pipeline.
- TrialA Phase II Study of SKB571 in Patients With Lung Cancer
Shares Sichuan Kelun-Biotech and the tag pipeline.
- TrialA Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities
Shares Sichuan Kelun-Biotech and the tag pipeline.
- TrialSKB103 for Injection in Advanced Solid Tumors
Shares Sichuan Kelun-Biotech and the tag pipeline.
- TrialSKB565 for Injection in Advanced Solid Tumors
Shares Sichuan Kelun-Biotech and the tag pipeline.
- TrialSKB118 Injection in Advanced Solid Tumors
Shares Sichuan Kelun-Biotech and the tag pipeline.
- TrialSKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
Shares Sichuan Kelun-Biotech and the tag pipeline.